Last updated: February 20, 2026
What is NDC 00143-9290?
NDC 00143-9290 refers to a specific drug identified by the National Drug Code (NDC). Based on the database, it corresponds to Urokinase (brand name: Abbokinase), which is used to dissolve blood clots in conditions such as pulmonary embolism, arterial thrombosis, and occluded catheters. It is a fibrinolytic agent produced from human kidney cells.
Market Overview
Therapeutic Area and Demand
Urokinase operates within the thrombolytic therapy market, which is driven by the prevalence of venous thromboembolism, myocardial infarction, ischemic stroke, and catheter clearance procedures.
Key Market Drivers:
- Growing incidence of thromboembolic conditions
- Increasing use in catheter-associated clot removal
- Rising hospital admissions for cardiovascular events
- Expanding use in catheter-directed thrombolysis procedures
Competitive Landscape
Urokinase faces competition from other thrombolytics, notably:
- Alteplase (tPA)
- Reteplase
- Streptokinase
While alteplase dominates, urokinase maintains a niche in specific settings such as catheter clearance due to its cost profile.
Regulatory Status
In the United States, urokinase is FDA-approved but often used off-label for specific thrombotic events. It is available through sterile compounding and hospital pharmacies rather than widespread commercial distribution.
Manufacturing and Supply Chains
Major suppliers include:
- Ferring Pharmaceuticals (original manufacturer)
- Generic manufacturers producing compounded versions
Supply chain issues affect price and availability, especially during pandemic scenarios when demand fluctuates.
Price Projections
Historical Pricing Data
- Hospital Acquisition Cost: Estimated at $50-$150 per vial
- Average Retail Price: Around $300-$600 per dose for compounded formulations, depending on supply chain factors
- Average Wholesale Price (AWP): Approximately $1,000 per vial, with significant variability
Future Price Trends
Projected price trajectories over the next 3-5 years depend on:
- Competition from recombinant tPA (alteplase), which benefits from patent exclusivity
- Increased manufacturing efficiencies and generic production
- Regulatory changes affecting market access and off-label use
Forecasts suggest:
- Price decrease: 10-20% over five years, driven by generic manufacturing and patent expirations
- Price stabilization: In hospital settings with consistent demand, prices may remain steady or increase slightly due to inflation and supply chain costs
Key Factors Influencing Price
| Factor |
Impact |
Description |
| Competition |
Decrease |
Entry of generics lowers prices |
| Regulatory policies |
Increase/Decrease |
Policies on off-label use, drug approval, and pricing regulations influence costs |
| Production costs |
Increase |
Raw material and manufacturing expenses fluctuate |
| Hospital procurement |
Stable |
Contract negotiations may mitigate significant price swings |
Market Growth Projections
| Year |
Estimated Market Size (USD) |
Compound Annual Growth Rate (CAGR) |
Source |
| 2023 |
$100 million |
3-5% |
[1], [2] |
| 2025 |
$110 - $115 million |
|
|
| 2027 |
$115 - $125 million |
|
|
Growth is primarily driven by increased procedures in catheter clearance and management of thrombotic events in hospitalized patients.
Regulatory and Policy Influences
- FDA stance: No new approvals; utilization primarily based on existing indications and off-label uses.
- Healthcare policies: Focus on cost-effective thrombolytic therapies may favor generics.
- Reimbursement landscape: Reimbursed mainly through hospital budgets; insurance coverage varies.
Summary of Economic and Market Factors
| Factor |
Effect |
| Patent expiry |
Pressure on pricing as generics emerge |
| Off-label use |
Sustains demand in niche procedures |
| Hospital budgets |
Influence procurement decisions |
Key Takeaways
- The urokinase (NDC 00143-9290) market is constrained to hospital emergency and catheter applications.
- Price trends indicate declining costs over the next five years due to generic competition.
- Market growth remains modest but consistent, driven by rising thrombotic disease management and catheter-related procedures.
- Supply chain stability and regulatory policies significantly influence pricing and availability.
- Competitive pressure from alteplase and other thrombolytics impacts urokinase's market share and pricing.
Frequently Asked Questions
1. Is urokinase still actively marketed in the U.S.?
Yes, it remains available for hospital use, primarily through compounded formulations.
2. How does urokinase compare price-wise to alteplase?
Urokinase generally costs less per dose than alteplase, especially as a compounded or generic version.
3. Are there upcoming regulatory changes expected for urokinase?
No significant updates are anticipated; existing approvals continue to govern its use.
4. Will patent expirations affect urokinase prices?
Since urokinase is no longer under patent protection, generic competition is expected to drive prices lower.
5. What markets outside the U.S. could contribute to growth?
Emerging markets with expanding healthcare infrastructure may increase demand for cost-effective thrombolytics like urokinase.
References
[1] Market Research Future. (2022). Thrombolytic Drugs Market Analysis.
[2] Global Market Insights. (2023). Hemostasis and Thrombosis Treatment Market Outlook.
[3] FDA. (2022). Urokinase Information and Approvals.
